Kite: Yescarta Quadruples Median Event-Free Survival Duration In Refractory Large B-Cell Lymphoma

FOSTER CITY (dpa-AFX) - Kite, a Gilead Company (GILD), said that yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory

Related Keywords

,Kostenloser Wertpapierhandel ,Gilead Company ,European Medicines Agency ,Drug Administration ,Second Line Relapsed ,Refractory Largeb Cell ,Event Free Survival ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,European Medicines ,Kite ,Descarta ,Quadruples ,Comedian ,Event ,Tree ,Survival ,Uration ,Refractory ,Barge ,Fell ,Lymphoma ,